Product Candidate

Thymosin Beta-4 in Dry Eye Syndrome

Dry eye syndrome (DES) is a common condition, affecting tens of millions of individuals and characterized by ocular surface inflammation. Patients may experience burning, irritation, foreign body sensation, fluctuating or blurred vision, and, in more severe cases, marked discomfort and reduced visual function.

Current wound-healing and anti-inflammatory options for the cornea remain limited, and some established agents are associated with tolerability challenges in certain patients. Thymosin beta-4 (Tβ4) has been investigated as a peptide with regenerative and anti-inflammatory properties on the ocular surface. In experimental and clinical studies, Tβ4 has been reported to promote corneal epithelial cell migration, decrease the expression of corneal epithelial cytokines and chemokines such as IL-1β and IL-8, and inhibit corneal polymorphonuclear (PMN) cell infiltration and adhesion to endothelium.

Clinical studies in dry eye have shown signals of improvement in both signs and symptoms of DES, accompanied by a favorable local tolerability profile in the populations studied. Björklund Pharma AS is evaluating Tβ4 within its regenerative medicine portfolio as a candidate for ocular surface disorders, with eventual clinical use dependent on the outcomes of further preclinical and controlled clinical investigations.

PubMed articles: https://bit.ly/3Rw9BxC